Biogen Deferred Taxes decreased by 85.9% to $23.60M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 184.9%, from -$27.80M to $23.60M. Over 2 years (FY 2022 to FY 2025), Deferred Taxes shows an upward trend with a 46.4% CAGR.
Positive values indicate tax benefits that improve cash flow, while negative values indicate cash tax outflows exceeding accounting expense.
This reflects the difference between income tax expense recognized in the financial statements and the actual tax payabl...
Common across all industries; highly dependent on specific tax jurisdictions and capital expenditure cycles.
deferred_income_taxes| Q2 '21 | Q3 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | -$607.80M | -$127.30M | $1.00M | -$48.50M | -$92.30M | -$28.80M | -$64.50M | -$106.40M | -$206.80M | $39.90M | -$87.00M | -$52.60M | -$58.40M | -$27.80M | -$31.30M | $253.80M | $166.90M | $23.60M |
| QoQ Change | — | +79.1% | +100.8% | <-999% | -90.3% | +68.8% | -124.0% | -65.0% | -94.4% | +119.3% | -318.0% | +39.5% | -11.0% | +52.4% | -12.6% | +910.9% | -34.2% | -85.9% |
| YoY Change | — | — | — | +92.0% | +27.5% | — | <-999% | -119.4% | -124.1% | +161.9% | +18.2% | +74.6% | — | -169.7% | +64.0% | +582.5% | +385.8% | +184.9% |